List of Excipients in Branded Drug TEGRETOL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	TEGRETOL	carbamazepine	0078-0508	CITRIC ACID MONOHYDRATE
Novartis Pharmaceuticals Corporation	TEGRETOL	carbamazepine	0078-0508	FD&C YELLOW NO. 6
Novartis Pharmaceuticals Corporation	TEGRETOL	carbamazepine	0078-0508	POTASSIUM SORBATE
Novartis Pharmaceuticals Corporation	TEGRETOL	carbamazepine	0078-0508	PROPYLENE GLYCOL
Novartis Pharmaceuticals Corporation	TEGRETOL	carbamazepine	0078-0508	SORBITOL
Novartis Pharmaceuticals Corporation	TEGRETOL	carbamazepine	0078-0508	SUCROSE

TEGRETOL Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

TEGRETOL is an established carbamazepine brand with no meaningful current composition-of-matter exclusivity barrier. Commercial opportunity is concentrated in formulation differentiation, pediatric acceptability, modified release, supply-chain optimization, and generic substitution rather than in blocking patents. The core products are immediate-release tablets, chewable tablets, oral suspension, and extended-release tablets. Carbamazepine remains technically demanding because of poor aqueous solubility, dose-related tolerability, narrow therapeutic use margins, polymorphism, and clinically important food and formulation effects.

What products and dosage forms does TEGRETOL contain?

TEGRETOL products are approved for epilepsy and trigeminal neuralgia. TEGRETOL XR is an extended-release carbamazepine product. FDA labeling identifies the active ingredient as carbamazepine and distinguishes the dosage forms by release profile and excipient system.[1,2]

Product	Dosage form	Representative strengths	Primary excipient strategy
TEGRETOL	Immediate-release tablet	200 mg	Direct-compression or conventional compressed-tablet system
TEGRETOL	Chewable tablet	100 mg	Mannitol-based, flavored, chewable matrix
TEGRETOL	Oral suspension	100 mg/5 mL	Aqueous suspension with suspending agents, sweeteners, preservatives and flavor
TEGRETOL XR	Extended-release tablet	100 mg, 200 mg, 400 mg	Controlled-release hydrophilic polymer matrix and film-coat system

The immediate-release tablets are the closest reference products for conventional generic competition. The suspension and chewable products create more opportunity for excipient-led differentiation because taste, sedimentation, redispersibility, dose uniformity and pediatric use directly affect product performance.

What excipients are used in TEGRETOL formulations?

Immediate-release tablets

The TEGRETOL tablet label identifies excipients that are typical of a conventional solid oral dosage form, including microcrystalline cellulose, povidone, crospovidone, colloidal silicon dioxide, magnesium stearate, sodium lauryl sulfate and talc.[1]

Their functional roles are commercially relevant:

Excipient class	Likely function in TEGRETOL tablets	Strategic relevance
Microcrystalline cellulose	Diluent and compression aid	Supports tablet hardness and manufacturability
Povidone	Binder	Controls granule strength and content uniformity
Crospovidone	Superdisintegrant	Accelerates tablet breakup
Colloidal silicon dioxide	Glidant	Improves powder flow
Magnesium stearate	Lubricant	Reduces tooling friction
Sodium lauryl sulfate	Wetting agent	Supports drug wetting and dissolution
Talc	Glidant or anti-adherent	Supports compression and processing

Carbamazepine has low water solubility. Sodium lauryl sulfate and particle-size control can materially affect wetting and dissolution. Excessive hydrophobic lubrication, particularly magnesium stearate, can slow dissolution if blending is poorly controlled. A generic developer should therefore treat lubricant concentration, blending time, drug particle size, polymorphic form and disintegration performance as a linked control strategy.

Chewable tablets

The 100 mg chewable dosage form uses excipients associated with palatability and chewability, including mannitol, flavor, microcrystalline cellulose, povidone, crospovidone, colloidal silicon dioxide, magnesium stearate, sodium lauryl sulfate and talc.[1]

Mannitol is commercially important because it provides a cooling mouthfeel and a less hygroscopic alternative to some sugar-based fillers. The main opportunity is not simply replacing mannitol. A successful reformulation must preserve:

• dose uniformity at the low 100 mg strength;
• acceptable mouthfeel;
• low grittiness;
• rapid dispersion after chewing;
• chemical stability;
• compatibility with carbamazepine polymorph control.

Taste masking is difficult because carbamazepine has a persistent, bitter sensory profile. Commercial approaches include polymeric taste-masking coatings, ion-exchange resin complexes, lipid barriers, co-processed excipients and multiparticulate delivery. Each approach introduces potential dissolution and bioequivalence risk.

Oral suspension

The oral suspension uses a multidimensional excipient system. The label identifies water-based suspension components, viscosity-building agents, sweetening agents, preservatives, flavoring agents and pH-control components.[1]

The most relevant functional categories are:

• suspending and viscosity agents, such as cellulose derivatives;
• sweeteners, including sorbitol and saccharin sodium;
• preservatives, including methylparaben and propylparaben;
• cosolvents or humectants, including propylene glycol;
• flavor systems;
• purified water.

The commercial performance of a carbamazepine suspension depends on more than chemical assay. Critical quality attributes include sedimentation volume, redispersibility, viscosity across temperature ranges, particle-size distribution, dose delivery through oral syringes, preservative effectiveness and taste.

A reformulated suspension can target pediatric and geriatric users with a lower-sugar profile, improved syringeability, reduced sedimentation and improved flavor masking. A sugar-free product may have commercial appeal, but polyol systems can create gastrointestinal tolerability concerns and may require careful label positioning.

Extended-release tablets

TEGRETOL XR uses a controlled-release tablet architecture rather than the immediate-release excipient profile. FDA labeling identifies hydrophilic film-forming and matrix-related excipients, along with standard tablet lubricants and coating components.[2]

The technical objective is to manage carbamazepine release over an extended interval while reducing peak-to-trough fluctuations. Relevant excipient categories include:

• hydrophilic matrix polymers;
• film-coating polymers;
• plasticizers;
• pore-forming or permeability-modifying agents;
• compression aids;
• lubricants and anti-adherents.

For an XR generic or follow-on product, the commercial barrier is formulation performance, not an active-ingredient patent. Release behavior must remain consistent across fed and fasted conditions and across manufacturing scale. Changes in polymer grade, particle size, coating weight, tablet hardness or dissolution apparatus parameters can change the release profile.

When does TEGRETOL lose exclusivity?

TEGRETOL's principal exclusivity periods expired decades ago. Carbamazepine is a long-established small-molecule active ingredient, and multiple generic carbamazepine products have been approved in the United States.

Exclusivity category	TEGRETOL position
Composition-of-matter patent	Expired
New chemical entity exclusivity	Expired
Original product patent barrier	Expired
Current small-molecule generic pathway	ANDA pathway under section 505(j)
Biosimilar pathway	Not applicable
Current commercial protection	Brand recognition, formulation know-how, distribution and product availability

The FDA Orange Book is the controlling source for listed patents and regulatory exclusivity for approved U.S. products.[3] For TEGRETOL, the practical market assessment is that generic entrants face formulation, bioequivalence, manufacturing and commercial execution risks rather than a durable branded patent wall.

What patents protect TEGRETOL formulations?

Historical patents covering carbamazepine products and controlled-release systems have generally expired. Current opportunity is more likely to arise from new patents on:

• taste-masked carbamazepine particles;
• orally disintegrating or rapidly dispersible formulations;
• pediatric suspensions with improved redispersibility;
• multiparticulate extended-release systems;
• abuse-resistant or adherence-oriented packaging;
• manufacturing processes that control carbamazepine polymorphs;
• co-processed excipient systems;
• specific dissolution profiles linked to fed-state performance.

A patent directed only to replacing one conventional excipient with another is likely to face validity and obviousness pressure. Stronger claims would combine a defined carbamazepine particle-size or polymorph parameter with a specific excipient ratio, process condition and clinically relevant dissolution result.

How strong is the patent estate for a new TEGRETOL formulation?

A new formulation patent can be commercially useful if it controls a product attribute that is difficult to design around. The strongest candidates are:

1. a stable pediatric suspension with demonstrably improved dose uniformity after storage and repeated withdrawals;
2. an XR product with a reproducible release profile under both fed and fasted conditions;
3. a taste-masked chewable or orally disintegrating product with preserved bioavailability;
4. a manufacturing process that consistently produces the required carbamazepine polymorph and particle-size distribution.

Weak claim strategies include broad claims to routine binders, lubricants, sweeteners or standard cellulose derivatives without unexpected performance data.

What FDA regulatory pathway applies to generic TEGRETOL?

Generic immediate-release carbamazepine tablets and suspensions generally proceed through an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the relevant reference-listed drug.[4]

Extended-release products require more complex development. The applicant must establish equivalent release behavior and meet FDA expectations for pharmacokinetic comparison, dissolution and, where applicable, fed-state performance. The reference product for an XR application cannot be treated as interchangeable with an immediate-release carbamazepine product merely because the active ingredient and strength are similar.

FDA's Inactive Ingredient Database can support excipient selection by showing prior use in approved products, route, dosage form and maximum daily exposure context.[5] Prior use does not eliminate the need to establish compatibility, stability, manufacturing control and product-specific performance.

Are Paragraph IV challenges relevant to TEGRETOL?

Paragraph IV challenges are most relevant when an applicant certifies that a listed patent is invalid, unenforceable or will not be infringed. Because the principal TEGRETOL patent barriers are historical, a new ANDA applicant would more likely face:

• no current listed patent barrier;
• a Paragraph III certification where an unexpired patent is listed but not challenged;
• a Paragraph IV certification if a later-listed formulation patent remains relevant;
• litigation risk involving formulation, labeling or manufacturing patents rather than carbamazepine itself.

Any current patent certification must be assessed against the live Orange Book listing for the precise reference product, dosage form and strength. A challenge to TEGRETOL tablets does not automatically resolve risk for TEGRETOL XR.

Which companies are challenging TEGRETOL?

Generic carbamazepine products have been marketed by multiple U.S. generic manufacturers, including large multisource suppliers. Competition is fragmented across immediate-release tablets, chewable tablets, suspension and extended-release products.

The relevant competitive groups are:

Competitive group	Main advantage	Main weakness
Large generic manufacturers	Scale, established ANDA infrastructure and pharmacy access	Lower margin and limited differentiation
Specialty generic companies	Reformulation and niche dosage-form expertise	Smaller sales force and manufacturing footprint
Branded-generic suppliers	Prescriber familiarity and controlled distribution	Higher selling expense
Excipients and CDMO companies	Formulation technology and process know-how	Dependence on a finished-dose sponsor

The most defensible opportunity is a differentiated dosage form rather than another conventional 200 mg tablet.

What commercial opportunities exist in TEGRETOL excipients?

Pediatric and geriatric liquid products

A carbamazepine suspension with improved taste, lower sedimentation and oral-syringe compatibility can compete on adherence and caregiver convenience. Excipients with the strongest commercial value are those that improve multiple attributes simultaneously, such as suspension stability, palatability and preservative robustness.

Chewable and orally disintegrating products

A low-dose, taste-masked product can target patients who cannot swallow tablets. Mannitol, co-processed fillers, polymeric taste barriers and low-moisture manufacturing are relevant technology areas.

Extended-release reformulation

A once-daily or more consistent extended-release product could compete where adherence and peak-related tolerability matter. The formulation must demonstrate reliable release under variable gastrointestinal conditions. Polymer selection, coating design and tablet geometry are central development variables.

Excipient substitution and supply security

The established product contains conventional excipients that may be vulnerable to supplier concentration, regional availability or price volatility. A dual-source strategy for microcrystalline cellulose, povidone, crospovidone, mannitol, cellulose suspending agents and preservatives can reduce manufacturing disruption.

A substitution program must evaluate:

• dissolution and disintegration;
• tablet hardness and friability;
• suspension rheology;
• impurity and degradation profiles;
• microbial control;
• packaging interaction;
• regulatory change requirements.

Geographic expansion

The United States, Europe, Japan and emerging markets apply different expectations for excipient documentation, elemental impurities, nitrosamines, preservatives, colorants and pediatric acceptability. A global formulation should minimize region-specific excipients where possible. Colorants and preservative systems can create avoidable regulatory and procurement complexity.

What manufacturing and intellectual-property barriers remain?

The main barriers are technical:

• carbamazepine's low solubility;
• polymorphic behavior;
• dose-dependent dissolution;
• sensitivity to particle size;
• XR release reproducibility;
• taste masking without delayed absorption;
• suspension redispersibility;
• scale-up of granulation, coating and blending;
• stability under heat and humidity.

Manufacturing patents can be more valuable than broad composition claims if they cover a reproducible process for controlling polymorph, particle size or release rate. Trade secrets involving granulation endpoint, coating parameters, polymer grade and blending sequence can also create meaningful barriers, although they do not prevent independent development.

What generic launch scenarios exist for TEGRETOL?

Launch scenario	Probability of commercial use	Margin profile
Conventional immediate-release tablet	High	Low
Additional generic suspension	Moderate	Low to moderate
Improved pediatric suspension	Moderate	Moderate to high
Chewable or orally disintegrating formulation	Moderate	Moderate to high
Extended-release generic	Moderate	Moderate
Novel once-daily formulation	Lower	High if clinically differentiated
Excipient-enabled specialty product	Moderate	High if protected and reimbursed

A conventional tablet launch requires scale and low cost. A differentiated suspension or chewable product can support higher pricing but requires clinical, regulatory and commercial evidence. An XR product can support a stronger position, but development time and bioequivalence risk are higher.

What is the revenue exposure for a TEGRETOL excipient strategy?

Revenue exposure depends on the dosage form selected:

• Immediate-release tablets have the largest unit-volume opportunity but the weakest pricing.
• Suspension has lower volume but greater opportunity for product-level differentiation.
• Chewable and orally disintegrating products can command specialty-generic economics if they address swallowing or adherence barriers.
• Extended-release products have higher technical value and potentially stronger pricing, but they carry greater development risk.

The commercial case should be built around addressable volume by dosage form, reimbursement status, generic penetration, supply reliability and the ability to secure formulation or process protection. Brand sales alone are not a sufficient proxy for excipient opportunity because carbamazepine prescribing is heavily exposed to multisource generic substitution.

Key Takeaways

• TEGRETOL is a mature carbamazepine brand with expired core exclusivity.
• The main commercial opportunity is formulation differentiation, not active-ingredient patent protection.
• Immediate-release tablets are highly competitive and price-sensitive.
• Suspension and chewable products offer the clearest excipient-led opportunities.
• Carbamazepine's low solubility, polymorphism and taste create real formulation barriers.
• TEGRETOL XR requires separate development and patent analysis from immediate-release products.
• Strong new patent claims should link excipient composition with measurable dissolution, stability, taste or dose-delivery results.
• Excipient substitution can improve supply security but must preserve product performance and regulatory comparability.
• Biosimilar risk is irrelevant because carbamazepine is a small-molecule drug.
• The most attractive commercial targets are pediatric suspension, taste-masked chewable or orally disintegrating products, and technically robust extended-release systems.

FAQs

Is carbamazepine an excipient-sensitive drug?

Yes. Particle size, polymorphic form, wetting agents, lubricant level and release-control polymers can affect dissolution and absorption.

Can a new carbamazepine excipient combination receive patent protection?

Yes, but routine substitution is weakly protectable. Stronger patents require defined composition limits, process controls and unexpected performance data.

Is TEGRETOL XR interchangeable with immediate-release carbamazepine?

No. Extended-release and immediate-release products have different pharmacokinetic and dosing characteristics and require separate regulatory evaluation.

Which excipient is most important for a carbamazepine suspension?

The suspending system is central, but commercial performance also depends on particle size, sweetener selection, preservative effectiveness, flavor masking and oral-syringe delivery.

Does TEGRETOL have biosimilar competition?

No. Carbamazepine is a chemically synthesized small molecule. Competition proceeds through generic drug pathways rather than the U.S. biosimilar pathway.

References

1. Novartis Pharmaceuticals Corporation. (2023). Tegretol (carbamazepine) tablets, chewable tablets, and suspension: Prescribing information. U.S. Food and Drug Administration.

2. Novartis Pharmaceuticals Corporation. (2023). Tegretol XR (carbamazepine extended-release tablets): Prescribing information. U.S. Food and Drug Administration.

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). Generic drug facts and information: Abbreviated new drug application process. FDA.

5. U.S. Food and Drug Administration. (2025). Inactive Ingredient Database. FDA.